Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 5, 2010, Pages 999-1004

  Bickel, Markus ^a   Anadol, Evrim ^b   Vogel, Martin ^b   Hofmann, Wolf Peter ^a   von Hentig, Nils ^a   Kuetscher, Johannes ^a   Kurowski, Michael ^c   Moench, Christian ^a   Lennemann, Tessa ^a   Lutz, Thomas ^d   Bechstein, Wolf Otto ^a   Brodt, Hans Reinhard ^a   Rockstroh, Jürgen ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c Vivantes Auguste Viktoria Klinikum   (Germany)

^d Infektiologikum   (Germany)

Author keywords

CYP450; Drug interactions; FK 506; OLTX; Pharmacokinetics

Indexed keywords

DARUNAVIR; EMTRICITABINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; TACROLIMUS; TENOFOVIR; ZIDOVUDINE; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTRIGLYCERIDEMIA; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; MORNING DOSAGE; NEPHROTOXICITY; RETROSPECTIVE STUDY; CASE REPORT; CHEMISTRY; DRUG INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; SERUM; VIROLOGY;

ADULT; ANTI-HIV AGENTS; DRUG INTERACTIONS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PYRROLIDINONES; RETROSPECTIVE STUDIES; RITONAVIR; SERUM; TACROLIMUS;

EID: 77953697687     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq054     Document Type: Article

References (20)

1. Sattler M, Guengerich FP, Yun CH et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20: 753-61.
2. Vincent SH, Karanam BV, Painter SK et al. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys 1992; 294: 454-60.
3. Paterson DL, Singh N. Interactions between tacrolimus and antimicrobial agents. Clin Infect Dis 1997; 25: 1430-40.
4. Christians U, Jacobsen W, Benet LZ et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Drug Metab Dispos 2003; 31: 1292-5.
5. van Heeswijk RP, Veldkamp A, Mulder JW et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 2001; 6: 201-29.
6. Hsu A, Grannemann G, Bertz R. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35: 275-91.
7. Bäckman L, Nicar M, Levy M et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. Transplantation 1994; 57: 519-25.
8. Winkler M, Jost U, Ringe B et al. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. Transplant Proc 1991; 23: 3153-5.
9. Alessiani M, Cillo U, Fung JJ et al. Adverse effects of FK 506 overdosage after liver transplantation. Transplant Proc 1993; 25: 628-34.
10. Moench C, Barreiros AP, Schuchmann M et al. Tacrolimus monotherapy without steroids after liver transplantation - a prospective randomized double-blinded placebo-controlled trial. Am J Transplant 2007; 7: 1616-23.
11. Winkler M, Pichlmayr R, Neuhaus P et al. Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation. Transpl Int 1994; 7 Suppl 1: S58-63.
12. Williams R, Neuhaus P, Bismuth H et al. Two-year data from the European multicentre tacrolimus (FK506) liver study. Transpl Int 1996; 9 Suppl 1: S144-50.
13. Jain AB, Venkataramanan R, Eghtesad B et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl 2003; 9: 954-60.
14. Schonder KS, Shullo MA, Okusanya O. Tacrolimus and lopinavir/ritonavir interaction in liver transplantation. Ann Pharmacother 2003; 37: 1793-6.
15. Guaraldi G, Cocchi S, Codeluppi M et al. Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation. Transplant Proc 2005; 37: 2609-10.
16. Hardy G, Stanke-Labesque F, Contamin C et al. Protease inhibitors and diltiazem increase tacrolimus blood concentration in a patient with renal transplantation: a case report. Eur J Clin Pharmacol 2004; 60: 603-5.
17. Teicher E, Vincent I, Bonhomme-Faivre L et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007; 46: 941-52.
18. Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 2009; 48: 931-9.
19. Eron JJ, Young B, Cooper DA et al. Switch to a raltegravir-based regimen verus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375: 396-407.
20. Tricot L, Teicher E, Peytavin G et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9: 1946-52.